GLP-1 & Metabolic
Metabolic health, appetite regulation, and modern weight management.
122 articles in GLP-1 & Metabolic · page 10 of 11
Compounded Semaglutide: The Risks and Realities
FDA found patients drew 5-20x the intended dose of compounded semaglutide. What to understand before entering that market.
Read →GLP-1s and Fatty Liver Disease (MASH): The Evidence
A phase 3 trial moved GLP-1 therapy for MASH from frontier to evidence. What ESSENCE actually showed, and what it left open.
Read →Microdosing GLP-1s: Evidence or Anecdote?
Sub-therapeutic GLP-1 dosing is popular online. The controlled evidence behind it is essentially nonexistent — here is why.
Read →GLP-1s for Sleep Apnea: Reading the SURMOUNT-OSA Data
SURMOUNT-OSA cut the apnea-hypopnea index by about 20-24 events an hour versus placebo. A real signal, mediated by weight loss.
Read →GLP-1 Side Effects: What the Trials Report
Nausea leads the list, but the full picture matters. What the controlled trial data actually documents, and at what rates.
Read →The GLP-1 Weight-Loss Plateau, Explained
Why the scale stops moving on a GLP-1, what is happening physiologically, and what the trial data says to expect at the plateau.
Read →GLP-1s and Muscle Loss: Protecting Lean Mass
DEXA substudies show roughly a quarter to a third of the weight lost is lean mass. What training and protein intake can do.
Read →Managing GLP-1 Nausea: What the Evidence Suggests
Most GLP-1 nausea is dose- and titration-related, usually mild, and fades with time. What the evidence suggests actually helps, and when.
Read →What Happens When You Stop a GLP-1?
Trials show most people regain a large share of lost weight after stopping a GLP-1. What the data says, and what predicts it.
Read →Retatrutide: The Triple Agonist on the Horizon
Phase 2 data put retatrutide at 24.2% weight loss in 48 weeks — the largest yet. Why that deserves both attention and restraint.
Read →Oral Semaglutide: Does the Pill Match the Injection?
The Wegovy pill is now FDA-approved. Trial data shows it can match the injection, if the strict dosing rules are followed.
Read →Tirzepatide: How the Dual Agonist Changed the Field
Tirzepatide hit 22.5% average weight loss in SURMOUNT-1 by targeting both GIP and GLP-1 receptors at once. Why that reset the field.
Read →